Reported figures and Equlion model projections for the next 5 years.
Metric
2025 (actual)
2026 (forecast)
2027
2028
2029
2030
2031
Trend
ROA
-131.5%
-162.99%
-235.36%
-502.23%
-517.3%
-511.93%
-507.15%
Gross Margin
96.55%
96.01%
96.01%
96.01%
96.01%
96.01%
96.01%
Sector average
-
17.71%
17.71%
17.71%
17.71%
17.71%
62.35%
Net Margin
-350.94%
-244.04%
-246.62%
-247.99%
-247.17%
-246.7%
-246.34%
Total Assets
Amounts in SEK (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for Oncopeptides AB (publ)? It covers the balance sheet, income statement and Equlion model projections.
SEK 135,399.00K
SEK 222,012.00K
SEK 74,477.21K
SEK 82,284.81K
SEK 93,757.83K
SEK 102,409.93K
SEK 108,443.21K
Sector average
-
SEK 2,900,240.60K
SEK 3,045,009.79K
SEK 3,280,286.42K
SEK 3,536,407.14K
SEK 3,762,908.71K
SEK 1,806,991.80K
Net Income
-SEK 249,585.00K
-SEK 291,273.67K
-SEK 348,913.17K
-SEK 393,650.17K
-SEK 455,333.70K
-SEK 502,118.45K
-SEK 534,667.05K
Sector average
-
-SEK 22,027.28K
-SEK 904.69K
-SEK 7,253.84K
-SEK 3,858.45K
-SEK 1,547.00K
-SEK 13,704.11K
Valuation
-
SEK 1,832,424.03K
SEK 2,195,038.33K
SEK 2,476,482.11K
SEK 2,864,537.74K
SEK 3,158,864.01K
SEK 3,363,629.67K
Sector average
-
SEK 5,151,301.60K
SEK 5,189,236.02K
SEK 5,317,343.69K
SEK 5,514,329.75K
SEK 5,636,782.17K
SEK 3,179,755.44K
Stock Price
-
SEK 4.81
SEK 5.76
SEK 6.49
SEK 7.51
SEK 8.28
SEK 8.82
Sector average
-
SEK 48.04
SEK 48.69
SEK 50.45
SEK 52.13
SEK 53.41
SEK 36.70
Oncopeptides AB (publ) (ONCO.ST) Financial Forecast | Equlion
